FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936228839> ?p ?o ?g. }

• W2936228839 abstract "BACKGROUND AND AIMS A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Since that publication, highly efficacious direct-acting antiviral therapies (DAAs) have become available, making HCV elimination a possibility. This analysis quantifies the clinical and economic burden of HCV intervention strategies over the next 15 years. METHODS A model was developed to estimate the future clinical and economic burden of HCV infection if patients are diagnosed and treated according to a historical paradigm (historical base case), or at higher levels without treatment reimbursement restrictions (Scenario 1). The infected population was tracked by age- and sex-defined cohorts, and associated direct medical costs (healthcare, screening, diagnostics and treatment) and quality-adjusted life years (QALYs) were calculated. Direct cost savings and the incremental cost-effectiveness ratio (ICER) were calculated to assess the economic impact of each scenario. Additionally, we generated a net-zero cost scenario (Scenario 2), assuming the same treatment paradigm as Scenario 1 but at the treatment price that would break even by 2031. RESULTS In the historical base case, annual direct costs are projected to decrease from 150 million (95% UI: 132–170 million) CHF in 2016 to 90 million (95% UI: 65–111 million) CHF in 2031. Cumulative direct costs are projected to reach 1.7 billion (95% UI: 1.2–2.0 billion) CHF by 2031. In Scenario 1, annual direct costs first increased to 175 million CHF by 2018, before declining to 44 million CHF by 2031. Cumulative direct costs in this scenario are projected to reach 1.8 billion CHF by 2031. For Scenario 2, the treatment price needed to achieve break-even by 2031 considering only direct costs would be 27,900 CHF per patient. By 2031, Scenarios 1 and 2 would gain 58,300 QALYs. In both scenarios, the ICER drops below the cost-effectiveness threshold of 78,000 CHF in 2018. Over the 15-year span, the ICER was determined to be 2,200 CHF for Scenario 1. CONCLUSIONS Increasing the number of patients treated and treating all fibrosis stages is cost-effective compared to the historical base case and could achieve break-even by 2031 at a price of 27,900 CHF." @default.
• W2936228839 created "2019-04-25" @default.
• W2936228839 creator A5026722725 @default.
• W2936228839 creator A5030105607 @default.
• W2936228839 creator A5065556120 @default.
• W2936228839 creator A5067681635 @default.
• W2936228839 creator A5087227508 @default.
• W2936228839 date "2019-03-24" @default.
• W2936228839 modified "2023-10-02" @default.
• W2936228839 title "Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland" @default.
• W2936228839 doi "https://doi.org/10.4414/smw.2019.20026" @default.
• W2936228839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30905063" @default.
• W2936228839 hasPublicationYear "2019" @default.
• W2936228839 type Work @default.
• W2936228839 sameAs 2936228839 @default.
• W2936228839 citedByCount "8" @default.
• W2936228839 countsByYear W29362288392021 @default.
• W2936228839 countsByYear W29362288392022 @default.
• W2936228839 crossrefType "journal-article" @default.
• W2936228839 hasAuthorship W2936228839A5026722725 @default.
• W2936228839 hasAuthorship W2936228839A5030105607 @default.
• W2936228839 hasAuthorship W2936228839A5065556120 @default.
• W2936228839 hasAuthorship W2936228839A5067681635 @default.
• W2936228839 hasAuthorship W2936228839A5087227508 @default.
• W2936228839 hasBestOaLocation W29362288391 @default.
• W2936228839 hasConcept C10138342 @default.
• W2936228839 hasConcept C112930515 @default.
• W2936228839 hasConcept C121955636 @default.
• W2936228839 hasConcept C126322002 @default.
• W2936228839 hasConcept C127413603 @default.
• W2936228839 hasConcept C127454912 @default.
• W2936228839 hasConcept C142724271 @default.
• W2936228839 hasConcept C144133560 @default.
• W2936228839 hasConcept C147176958 @default.
• W2936228839 hasConcept C159047783 @default.
• W2936228839 hasConcept C160735492 @default.
• W2936228839 hasConcept C162324750 @default.
• W2936228839 hasConcept C18785705 @default.
• W2936228839 hasConcept C188897 @default.
• W2936228839 hasConcept C18903297 @default.
• W2936228839 hasConcept C194828623 @default.
• W2936228839 hasConcept C2522874641 @default.
• W2936228839 hasConcept C2776125615 @default.
• W2936228839 hasConcept C2776408679 @default.
• W2936228839 hasConcept C2776455275 @default.
• W2936228839 hasConcept C2779703844 @default.
• W2936228839 hasConcept C2780664029 @default.
• W2936228839 hasConcept C2908647359 @default.
• W2936228839 hasConcept C3019080777 @default.
• W2936228839 hasConcept C50522688 @default.
• W2936228839 hasConcept C515549039 @default.
• W2936228839 hasConcept C64332521 @default.
• W2936228839 hasConcept C6964187 @default.
• W2936228839 hasConcept C71924100 @default.
• W2936228839 hasConcept C86803240 @default.
• W2936228839 hasConcept C99454951 @default.
• W2936228839 hasConceptScore W2936228839C10138342 @default.
• W2936228839 hasConceptScore W2936228839C112930515 @default.
• W2936228839 hasConceptScore W2936228839C121955636 @default.
• W2936228839 hasConceptScore W2936228839C126322002 @default.
• W2936228839 hasConceptScore W2936228839C127413603 @default.
• W2936228839 hasConceptScore W2936228839C127454912 @default.
• W2936228839 hasConceptScore W2936228839C142724271 @default.
• W2936228839 hasConceptScore W2936228839C144133560 @default.
• W2936228839 hasConceptScore W2936228839C147176958 @default.
• W2936228839 hasConceptScore W2936228839C159047783 @default.
• W2936228839 hasConceptScore W2936228839C160735492 @default.
• W2936228839 hasConceptScore W2936228839C162324750 @default.
• W2936228839 hasConceptScore W2936228839C18785705 @default.
• W2936228839 hasConceptScore W2936228839C188897 @default.
• W2936228839 hasConceptScore W2936228839C18903297 @default.
• W2936228839 hasConceptScore W2936228839C194828623 @default.
• W2936228839 hasConceptScore W2936228839C2522874641 @default.
• W2936228839 hasConceptScore W2936228839C2776125615 @default.
• W2936228839 hasConceptScore W2936228839C2776408679 @default.
• W2936228839 hasConceptScore W2936228839C2776455275 @default.
• W2936228839 hasConceptScore W2936228839C2779703844 @default.
• W2936228839 hasConceptScore W2936228839C2780664029 @default.
• W2936228839 hasConceptScore W2936228839C2908647359 @default.
• W2936228839 hasConceptScore W2936228839C3019080777 @default.
• W2936228839 hasConceptScore W2936228839C50522688 @default.
• W2936228839 hasConceptScore W2936228839C515549039 @default.
• W2936228839 hasConceptScore W2936228839C64332521 @default.
• W2936228839 hasConceptScore W2936228839C6964187 @default.
• W2936228839 hasConceptScore W2936228839C71924100 @default.
• W2936228839 hasConceptScore W2936228839C86803240 @default.
• W2936228839 hasConceptScore W2936228839C99454951 @default.
• W2936228839 hasLocation W29362288391 @default.
• W2936228839 hasLocation W29362288392 @default.
• W2936228839 hasOpenAccess W2936228839 @default.
• W2936228839 hasPrimaryLocation W29362288391 @default.
• W2936228839 hasRelatedWork W1821706753 @default.
• W2936228839 hasRelatedWork W1911068332 @default.
• W2936228839 hasRelatedWork W2100804811 @default.
• W2936228839 hasRelatedWork W2921974896 @default.
• W2936228839 hasRelatedWork W2936228839 @default.
• W2936228839 hasRelatedWork W3033232281 @default.
• W2936228839 hasRelatedWork W3196394791 @default.
• W2936228839 hasRelatedWork W3202097937 @default.
• W2936228839 hasRelatedWork W4224949121 @default.

• next